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Abstract
Clinical practice and public health guidelines are important tools for translating research findings into practice with
the aim of assisting health practitioners as well as patients and consumers in health behavior and healthcare
decision-making. Numerous programs for guideline development exist around the world, with growing
international collaboration to improve their quality. One of the key features in developing trustworthy guidelines is
that recommendations should be based on high-quality systematic reviews of the best available evidence. The
review process used by guideline developers to identify and grade relevant evidence for developing
recommendations should be systematic, transparent and unbiased. In this paper, we provide an overview of
current international developments in the field of practice guidelines and methods to develop guidelines, with a
specific focus on the role of systematic reviews. The Guidelines International Network (G-I-N) aims to stimulate
collaboration between guideline developers and systematic reviewers to optimize the use of available evidence in
guideline development and to increase efficiency in the guideline development process. Considering the
significant benefit of systematic reviews for the guideline community, the G-I-N Board of Trustees supports the
international prospective register of systematic reviews (PROSPERO) initiative. G-I-N also recently launched a Data
Extraction Resource (GINDER) to present and share data extracted from individual studies in a standardized
template. PROSPERO and GINDER are complementary tools to enhance collaboration between guideline
developers and systematic reviewers to allow for alignment of activities and a reduction in duplication of effort.
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Background
Clinical practice and public health guidelines are “sys-
tematically developed statements designed to help prac-
titioners and patients to make decisions about
appropriate healthcare for specific circumstances” [1] (p.
38). The Institute of Medicine recently updated this
early definition to underscore the importance of sys-
tematic review of the evidence and both benefits and
harms assessment as essential characteristics of practice
guidelines: “Clinical practice guidelines are statements
that include recommendations intended to optimize
patient care, that are informed by a systematic review of
evidence and an assessment of the benefits and harms
of alternative care options” [2] (p. 4). In healthcare ser-
vices, clinical guidelines are considered important
instruments with which to improve and manage the
care process [3-6]. Important goals in developing and
implementing guidelines are higher quality and
improved cost-effectiveness of interventions, ideally
resulting in improved health outcomes [7,8].
The growing body of knowledge in the field of clinical
guidelines has provided opportunities for international
collaboration. In 2002, the Guidelines International Net-
work (G-I-N) was founded to provide a network and
partnerships for guideline organizations, implementers,
researchers and other stakeholders in healthcare [9]. G-
I-N seeks to improve the quality of health care by
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promoting the systematic development of guidelines and
their application to practice.
One of the key features in developing guidelines is to
ensure that guideline recommendations are based, as
much as possible, on high-quality systematic reviews of
the best available evidence. Similarly, the review process
used by guideline developers to identify and grade rele-
vant evidence for developing recommendations should
be systematic, transparent and unbiased. The medical
literature is expanding quickly [10], and ongoing colla-
boration between guideline developers and systematic
reviewers is needed to maximize the use of the best
available evidence to support guideline recommenda-
tions. The international prospective register of systema-
tic reviews (PROSPERO) is a promising new initiative
whose purpose is to stimulate collaboration, reduce
duplication of research efforts and improve quality [11].
In this paper, we introduce the international guideline
community and describe current methods for develop-
ing guidelines with a specific focus on the role of sys-
tematic reviews in guideline development. The aim of
this paper is to create common ground for guideline
developers and systematic reviewers on which to base
their collaboration.
The Guidelines International Network (G-I-N)
G-I-N is a global network which comprises 93 organiza-
tions and 89 individuals as members representing 46
countries from all continents (as of January 2012). The
network supports evidence-based healthcare and
improvement of health outcomes throughout the world.
The specific aims of G-I-N are to promote best practices
and reduce duplication of research efforts by improving
the efficiency and effectiveness of evidence-based guide-
line development, adaptation, dissemination and imple-
mentation. One of the main assets of G-I-N is its
International Guideline Library. The library contains
more than 7,400 documents (as of January 2012) and
includes guidelines (N = 3,636), evidence reports, meth-
odologies and other related documents developed or
endorsed by G-I-N member organizations [12].
A recent, important new product of G-I-N in relation
to systematic reviews has been developed by G-I-N’s
Evidence Tables Working Group. This group has devel-
oped a minimum data set that can be used to summar-
ize published studies. A template for intervention
studies has been developed [13] in addition to a tem-
plate for diagnostic studies. Templates for healthcare
economic and prognostic studies are in preparation. The
templates allow for consistent comparison across studies
and to inform a group process in synthesizing evidence.
On this basis, a resource has been developed to allow
reviewers to present data extracted from individual stu-
dies using a standardized template (called a “summary”
for short). This resource forms the foundation for devel-
opment of evidence tables which summarize data based
on a defined question. The summaries can then be used
by G-I-N members in their guideline development pro-
cess to populate their evidence tables using the data
directly as presented in the original research articles or
modified according to their specific needs. The registry
was launched in August 2011 at the Eighth G-I-N Con-
ference in Seoul under the acronym of GINDER: G-I-N
Data Extraction Resource [12].
Methodology for guideline development
Methods for guideline development have been harmo-
nized to a certain degree [14,15]. Core elements of the
process are formulating the relevant healthcare clinical
questions, identifying relevant outcomes, systematically
identifying and summarizing the relevant evidence,
synthesizing the evidence by evaluation of its quality
and formulating recommendations for daily practice or
healthcare policy. The steps in guideline development
are given in Table 1.
A standard guideline development process is essential
to ensuring that developers publish valid, reliable guide-
lines that can be used in their research. The Appraisal
of Guidelines, Research and Evaluation (AGREE II)
instrument is a valuable tool with which to analyze the
rigor of development of a good guideline [16], and stan-
dards for guideline development have been developed at
the national level, such as the recently published stan-
dards for trustworthy guidelines issued by the Institute
of Medicine [2]. Thus far, however, the guideline com-
munity has not established a common set of interna-
tionally recognized standards to help improve the
development of high quality guidelines. International
standards will facilitate information sharing and adapta-
tion to reduce duplication of efforts and support initia-
tives for the development of high-quality national or
local guidelines. The G-I-N Board of Trustees recently
prepared a position paper with key components describ-
ing how to develop and evaluate quality clinical practice
guidelines (Qaseem A. et al, Guidelines International
Network: Towards International Standards for Clinical
Practice Guidelines, Annals of Internal Medicine
2012;156 (forthcoming)). This position paper should
contribute to further harmonization of the guideline
development process and stimulate the development of
international guideline standards.
The role of systematic reviews in guideline
development
Recommendations in guidelines are typically derived
from a set of key questions for prevention, diagnosis
and/or treatment for the target group of patients. Key
questions should include elements that will guide the
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literature review process: the familiar patient problem or
population, intervention, comparison and outcomes
(PICO) format [17]. Other issues to be considered are
the importance of the effectiveness of interventions by
estimating the effect sizes for the relevant outcomes and
whether the desirable effects (benefits) outweigh the
undesirable effects (harms) [18]. Weighing benefits and
harms also requires the collection of empirical data or
qualitative information about the values and preferences
of patients.
The literature review to identify and summarize the
evidence must be carried out in such a way that the
potential for any bias is minimized. Some manuals of
national guideline programs include the production of
full systematic reviews, whereas others primarily identify
existing systematic reviews and conduct additional
reviews if necessary and feasible [19-23]. Depending on
the number of questions, multiple systematic reviews
may be required to inform a guideline. A recent editor-
ial published in the Cochrane Database of Systematic
Reviews shows that the National Institute of Health and
Clinical Excellence frequently uses the Cochrane reviews
in issuing guidelines, although the authors of the editor-
ial advocate better use of Cochrane reviews, as well as
more collaboration between groups, in developing
guidelines [24]. Another option used by guideline devel-
opers is to identify evidence in existing guidelines,
because guideline databases are growing [12,25].
Systematic reviews intended to inform the develop-
ment of clinical guidelines should follow principles out-
lined in published checklists such as the PRISMA
statement for transparent reporting of systematic
reviews and meta-analyses [26]. The Institute of Medi-
cine recently published standards for systematic reviews,
which include a standard for interaction between guide-
line developers and systematic reviewers [27]. Use of an
explicit and transparent strategy to evaluate evidence
helps users to interpret the relative strength of the evi-
dence [28,29]. Identified studies are systematically
appraised by assessing the methodological quality and
relevance of the clinical context in the study. On the
basis of the quality of individual studies, an overall
synthesis of the evidence will result in evidence state-
ments, usually expressed as levels of evidence. The
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach is increasingly being
adopted by guideline development organizations world-
wide [18]. The use of observational data has been advo-
cated to create evidence for everyday practice needs,
and adaptive approaches have been proposed to synthe-
size evidence using outcomes of both randomized trials
and observational research [30,31]. International colla-
boration to address these issues is important for build-
ing a body of knowledge and standards in guideline
development.
Translating evidence into recommendations for
clinical practice
Once the evidence is identified and appraised, the guide-
line development group must consider its relevance and
applicability to practice, including anticipated benefits
and harms, to formulate recommendations that can be
put into action [32]. Guideline developers must make a
considered judgment about the generalizability, applic-
ability, consistency and clinical impact of the evidence
to create a clear link between recommendations and the
underlying evidence. This is a crucial part of the guide-
line development process in which local circumstances
need to be taken into account. The strength of recom-
mendations included in guidelines is usually subject to a
grading system, such as the GRADE approach, that
takes into account the quality of the evidence and the
considered judgment of the guideline developers [18].
Transparency of the considered judgment of guideline
development groups is important to understanding the
arguments for specific recommendations. Guideline
recommendations should be expressed in clear, unam-
biguous language to facilitate implementation [33].
Table 1 Elements in guideline developmenta
Elements Specification
1. Organization and structure National or professional coordinated program. Development by (multidisciplinary) working groups, including
healthcare practitioners, systematic reviewers and/or methodologists and patients.
2. Preparation Definition of scope and objectives. Formulation of health and clinical questions and patient-important outcomes.
Specification of targeted patient or population groups and intended users.
3. Development process Identification of evidence via systematic literature search. Assessment and synthesis of evidence. Translation of
evidence into recommendations for daily practice and health policy.
4. Validation External review of draft guidelines by peers and stakeholders, as well as, if feasible, by field-testing.
5. Dissemination and
implementation
Publication on paper and/or electronically via website or journal. Further implementation via tailored strategies to
promote the actual use of the guideline.
6. Evaluation and revision Regular update based on scheduled review (every 3 to 5 years) and updating procedure.
aSource: Van der Wees et al. [15].
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Perspective for collaboration
Because developing new systematic reviews and using
existing ones are essential components of the guideline
development process, there is clearly potential for better
collaboration between guideline developers and systematic
reviewers. Interaction between guideline developers and
systematic reviewers is important for formulating PICO
questions, conducting the review of the evidence, compil-
ing the evidence tables and summarizing and presenting
the evidence. Resource constraints on guideline develop-
ment may limit the number of new systematic reviews
that can actually be carried out in a guideline project. In
addition, many systematic reviews do not meet the stan-
dards that are essential for use in developing a good guide-
line [2,27]. Collaborative approaches to further
improvement of the quality of systematic reviews and the
use of high-quality reviews in translating evidence into
guideline recommendations are therefore essential.
Alderson and Tan [24] made a plea for better use of
Cochrane reviews in guideline development, and PROS-
PERO may help to achieve that objective. A crucial fac-
tor in fostering better collaboration is alignment of
activities at the very start of the process. Guideline
developers should be aware of existing or expected sys-
tematic reviews to support their project, and systematic
reviewers should be aware of the relevant healthcare or
clinical questions in focusing their reviews. The prospec-
tive registration of systematic review protocols provides
an excellent basis from which to seek alignment and
create opportunities for including systematic reviewers
as members of the guideline development group. Identi-
fication of upcoming or existing systematic reviews can
reduce the workload and resources needed for guideline
development. The participation of systematic reviewers
in the guideline development process enhances the
application of their research findings to practice and
help bridge the gap between research and practice. The
GINDER registry of evidence summaries can further
enhance collaboration and reduce duplication of efforts.
G-I-N and PROSPERO have recognized the possibility
of closer collaboration and have started to encourage
their members and affiliates to work together. G-I-N sti-
mulates its members to use PROSPERO in searching for
published systematic reviews and systematic review pro-
tocols, and G-I-N promotes the registration of systematic
reviews within guideline development projects. PROS-
PERO has created a link to G-I-N’s website to raise
awareness among systematic reviewers of the potential
impact of their work on the development of guideline
recommendations and to facilitate the use of GINDER.
Conclusion
A registry of high-quality systematic reviews based on
rigorous standards is a topic of international interest.
We think that the international prospective register of
systematic reviews is of significant value for the interna-
tional guideline community. This paper summarizes the
view of G-I-N’s Board of Trustees that high-quality sys-
tematic reviews are essential for developing good clinical
practice and public health guidelines and that G-I-N
supports the PROSPERO initiative. PROSPERO and
GINDER are important complementary tools with
which to enhance collaboration between guideline devel-
opers and systematic reviewers and allow for alignment
of activities and reduced duplication of efforts.
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